Cytokine-Based Cancer Immunotherapies Summit

This is the primary industry platform dedicated to providing you insight into the latest clinical results and stimulating discussions around
how to take cytokine-based immunotherapy combinations forward.

The renewed interest in the anti-tumor properties of cytokines has led to an increase in the number of clinical trials that explore the safety and efficacy of cytokine-based drugs, not only as single agents, but also in combination with other immunomodulatory drugs.

Therapeutically targeting of soluble immune modulators in the tumor microenvironment (TME) has been shown to create a 'hot' tumor, increasing T cell infiltration and improving response rates to immune checkpoint blockade treatment. The immuno-oncology research community is pivoting towards engineering soluble factors and cytokines to transform the TME into an immunostimulatory state, acting as a complementary strategy to a suite of cancer immunotherapies approaches.

The virtual Cytokine-based Cancer Immunotherapies Summit has been established to give drug developers insight into the latest clinical advancements and stimulate discussions around how to take immuno-oncology combinations forward to meet the vast unmet need of cancer patients.

Join us and leading experts from Roche, CytomX, Philogen, Bristol-Myers Squibb, Novartis and many more to discuss how to reduce toxicity and achieve an efficacious dose, determining the mechanisms of action and hear the latest data coming out of the clinic.

Running digitally March 24-25, 2021.

Group discounts and early booking rates are available. Please visit the website for full pricing information.

URLs:
Tickets: https://go.evvnt.com/708655-1?pid=176 
Brochure: https://go.evvnt.com/708655-2?pid=176 

Time: 08:00 to 17:00

Prices:
Digital Conference Only - Drug Developer Pricing: USD 1999.00,
Digital Conference Only - Service Provider Pricing: USD 2499.00,
Digital Conference Only - Academic Pricing: USD 1799.00

Speakers: Ruth Ganss, Professor in Translational Cancer Research, Harry Perkins Institute of Medical Research, University of Western Australia, Milos Miljkovic, Assistant Research Physician Center for Cancer Research, National Cancer Institute, Heather Brodkin, Associate Director, Protein Engineering, Werewolf Therapeutics, Phillipe Foubert, Director - Tumor Microenvironment Translational Biomarkers, Bristol-Myers Squibb Co., Christian Klein, Head Oncology Programs, Department Head Cancer Immunotherapy Discovery 3, Roche Pharma Research and Early Development, Geraldine O'Sullivan Coyne, Staff Clinician, Developmental Therapeutics Clinic, National Cancer Institute, Angelo Corti, Professor of Biochemistry, San Raffaele University, Pushpa Jayaraman, Associate Director, Novartis Institutes for Biomedical Research, Dario Neri, Co-CEO and CSO, Professor, Philogen and ETH Zürich, Bruce Keyt, Chief Scientific Officer, IGM Biosciences, Robert Kastelein, Head of Therapeutic Discovery, Synthekine, Jamie Spangler, Assistant Professor, Johns Hopkins University, Jon Wigginton, Chief Medical Officer, Cullinan Oncology, Erwan Le Scolan, Senior Scientist II, CytomX Therapeutics, Michael Atkins, Acting Chief, Division of Hematology/ Oncology, Georgetown University Hospital, Katherine Seidl, Vice President, Immunology Strategy, SQZ Biotechnologies, Fahar Merchant, CEO, Medicenna, Carl Walkey, VP, Corporate Development, Neoleukin Therapeutics